IQVIA
TECHNOLOGIES

AI in Change Management: A Key Enabler for Data-Driven Tech in Medical Device Manufacturing and Registrations

ANUSHA GANGADHARA, Associate Director, Product Owner, SmartSolve Quality and Regulatory Solution, IQVIA
DR. SANJA MATERN, Director, Regulatory Affairs, Regulatory Information Management, Fresenius Medical Care

Table of contents

Introduction

MedTech companies including medical devices, in vitro diagnostics and software applications that support and enhance patient care operate under intense regulatory scrutiny while racing to innovate. Product and quality changes, whether driven by planned design updates, new requirements, process improvements, supplier changes, software releases or evolving regulations, require controlled, traceable, and auditable implementation to ensure compliance, patient safety, and market approvals.

Change requests: A recurring regulatory challenge

'A Saudi customer who attended the conference in the U.S. wants to know when the latest AI feature can be added to their diagnostic equipment'…..'The pediatric extension of the adult screener has strong demand in India — what is the timeline for legal availability there?'…..'The new labeling could perform well in Japan — is three months a realistic timeframe for approval?'

Sounds familiar, right? Regulatory teams are frequently confronted with targeted requests — almost on a quarterly or even monthly basis — for updates and timelines regarding new features, product extensions, or market clearances. These requests often come with an underlying hope for a rapid solution or an easy fix, as if a magical wand could instantly deliver the desired outcome. *Or is there really one*?

Addressing such inquiries requires careful coordination and adherence to regulatory processes, making quick turnarounds challenging despite the urgency expressed by stakeholders. The rigorous frameworks include major regulations and standards formulated by FDA 21 CFR, EU MDR/IVDR, QMSR and ISO 13485, ISO 14971 and 62304 etc., along with the GxP principles adding further dimensions and considerations as we go through global markets — and across the risk classifications. Each change could potentially trigger cascading activities such as design file updates, component changes, validation protocols, labeling revisions, or clinical evidence updates, and may impact safety, efficacy, and market approvals. Traditional change control is often slow, manual, and siloed, leading to:

Decision latency: Scattered data, lengthy access and interpretation times, and long approval cycles requiring manual intervention. Many organizations still rely on spreadsheets, emails, and static documents, which are error-prone and inefficient

Data and functional silos: Engineering, quality, regulatory affairs, manufacturing, and clinical teams often operate in separate systems with disconnected datasets

Documentation burden: High-volume, complex changes, particularly for software and AI-driven connected devices, span design files and records (DHF/DMR/DHR), Technical Documentation (TD), and registration documentation, cutting across multiple countries and languages

Regulatory risk blind spots: With incomplete impact analyses done in fragmented sessions, regulatory uncertainty to determine whether a change requires notification, submission, or approval by regulatory authorities can be complex

Cost of non-compliance: Including observations, warning letters, rework, and recalls, driven by limited predictive capabilities in traditional change management, which is reactive and focuses on managing changes after issues arise rather than anticipating them

Artificial Intelligence (AI) could prove to be a practical accelerator for this discipline, addressing these pain points by making change management more data-driven, predictive and automated. Applied thoughtfully, AI augments change management by automating routine tasks, predicting risk, and connecting the digital thread from R&D to registration. The result: faster, safer, and more compliant delivery of devices to patients worldwide.

AI in change controls across QARA

Change management in MedTech refers to the systematic process of proposing, evaluating, approving, implementing, and verifying changes that may affect a medical device or its quality system. The following table highlights key AI-driven features designed to streamline and enhance change management within regulatory and quality assurance (QARA) systems. Each feature targets a specific challenge in the traditional process, illustrating how advanced technologies can automate core tasks, improve decision-making, and ensure compliance across global markets. These design considerations are essential for a connected, modern QARA system that supports faster and more effective device delivery worldwide.

FEATURES	DESCRIPTION
Intelligent workflows	
Auto-triage and routing	Proposal for classification of change requests driven by internal activities or global publications (standards, regulations and guidelines) by using specific defined types, applicability, criticality and impacts, and routing to appropriate boards (like change and material review boards)
Auto-identification of impacts	Proposal for impacts on products affected by markets and registrations, driven by mapped types, change impacts, standards and regulations directly against product metadata and documentation
Adaptive approval path for changes	Propose best route for commercialization based on device classification, approval history, predicate information, site and market in consideration
Predictive impact analysis	
BOM effect estimation	Identify upstream/downstream artifacts — drawings, specifications, test methods, labeling, IFUs, UDI records — that need updates
Regulatory delta mapping	Predict which CER/CEP, PMCF, 510(k)/De Novo/PMA supplements, or technical documentation sections are affected
Validation scope recommendations	Suggest what must be reverified (IQ/OQ/PQ, software regression, cybersecurity testing, biocompatibility, sterilization validations)
Risk and quality compliance Intelligence	
Automated hazard linkage	Map changes to known hazards, harms, and controls per ISO 14971; flag residual risk changes
Audit-readiness checks	Validate that electronic records meet Part 11 controls; highlight missing signatures, time stamps, and traceability links
Signal detection for complaints and feedback	Mine complaints, NCs/CAPAs, SCARs, and PMS/PMCF data to surface latent risks impacted by the change
Connected data fabric across QARA processes (Digital Thread)	
Semantic search across repositories	DHF, DMR/DHR, PLM, QMS, MES, LIMS, LMS, eQMS, EDMS, and Regulatory Publishing Systems (RIMS)
Knowledge graphs	Maintain entity relationships (requirements → design → tests → validations → submissions → post-market evidence)
Master data alignment	Sync UDI, part numbers, suppliers, versions, and controlled vocabularies to ensure consistent records

Artificial intelligence can further transform manufacturing and quality processes by enabling real-time visibility, traceability, and knowledge reuse (herd wisdom). In manufacturing and quality, AI can be used to optimize processes, triage deviations, and evaluate supplier changes to improve efficiency and compliance. For software-related products, it can automate code impact mapping and prioritize regression testing based on risk. All of which finally trickles down to further AI assisting with document classification, content extraction, and tailoring registration materials to meet global requirements, streamlining the path to compliance across different markets.

A layered approach: Architecture and dynamic data handling

Key components include a data ingestion layer that connects to and refreshes live regulatory releases worldwide to ensure the most current compliance requirements are available for processing. Layered AI services drawing from this data layer support QARA processes and management, including Natural Language Processing (NLP), graph-based traceability, risk prediction, and generative AI for document drafting. Governance and security measures ensure compliance and integrity, while the experience layer integrates change control and analytics into existing workflows. Data quality is upheld through golden records, strict lineage tracking, and the use of dynamic standardized vocabularies.

AI as a catalyst for data-driven technology

AI-driven architecture and data handling enhance compliance and efficiency in manufacturing and quality processes by automating tasks, improving data integration, and supporting regulatory requirements. This sets the stage for tangible commercial benefits across teams and geographies through real-time visibility. The foundational AI capabilities described in the previous sections enable the advanced outcomes outlined next, such as unified dashboards, automated record connections, and the use of historical data for ongoing compliance and organizational improvement. Some examples include:

Real-time visibility and control

AI-powered dashboards unify quality, manufacturing, and regulatory metrics, enabling faster and more informed decision-making while minimizing unexpected issues. Examples include regulatory assessment and submission dashboard tracking and evaluation of regulatory KPIs such as First Time Right (RFT), Average submission cycle times for change completion).

Traceability and explainability

Artificial intelligence improves traceability by automatically connecting related records and providing clear explanations for changes, which is essential for building trust with auditors and regulatory/quality leaders. (Quality KPIs: Reduction in CAPA, observations in audits).

Scalable knowledge reuse

AI models leverage historical change data to identify effective strategies and standardize practices, creating an organizational memory that supports regulatory compliance and efficiency over time while leveraging new guidelines and regulations. (Regulatory KPIs: Submission velocity, time to agency responses).

AI operating model: Process + people + governance

Process and reference data enhancements

Logical standardization and the development of a strong regulatory backbone across markets are essential. This includes tiered classification frameworks for changes (minor, major, and market-impacting) and risk-driven validation approaches. Decision logic for no-impact, partial, and full revalidation should be codified, with structured checklists embedded per device, per class, and per market as a foundational layer.

People and skills

An environment that promotes AI literacy is critical. Regulatory affairs, quality assurance, manufacturing, and product teams should be upskilled to use AI effectively, including prompt enrichment for documentation tasks and the interpretation of AI-generated outputs. A strong culture of human-in-the-loop oversight must be fostered, ensuring that accountability and final decision-making remain with qualified personnel.

Governance and controls

Robust governance requires clearly defined protocols, performance thresholds, drift monitoring, and re-approval cycles throughout the AI lifecycle. Guardrails against hallucinations should mandate citation-backed outputs for regulatory artifacts, supported by maintained explainability logs. Audit readiness must be ensured by preserving change rationale, approvals, AI recommendations, and overrides, each captured with time-stamped records.

Taking MedTech change control further with AI

Advanced AI-driven approaches in MedTech change control could be defined across the PLM using:

1. Digital *Twin module* to mirror manufacturing and quality controls and processes by simulating the potential effects of process changes on manufacturing yield, sterilization, and patient safety before implementation as they get defined in the QMS change controls.

2. Generative regulatory intelligence is another important concept to enable dynamic gap analysis aligned with evolving regulations such as but not limited to MDR/IVDR and FDA QMSR, including automated updates to technical documentation driving market readiness.

3. Continuous post-market feedback loops integrate real-world data and service logs to keep risk assessments current with the latest FMEA processes. Contextual AI agents could act as tailored copilots within PLM/eQMS systems for specialized roles in regulatory affairs, quality assurance, manufacturing, and software, supporting efficient and compliant change management.

Operational challenges with AI implementation

Despite its potential, the use of AI in MedTech change management also presents challenges:

- Data quality and availability: AI models are only as good as the data they are trained on. Incomplete or inconsistent data can limit effectiveness

- Regulatory acceptance: Regulators may scrutinize AI-driven decision-making, especially if it replaces human judgment

- Explainability and transparency: AI output must be understandable and justifiable, particularly for audits and inspections

- Change management for people: Implementing AI itself is a change that requires training, trust-building, and cultural adaptation

- Cybersecurity and data privacy: AI systems must be secure and compliant with data governance and protection requirements

Successful implementation therefore requires a balanced approach that combines AI capabilities with strong governance and human oversight.

Conclusion

While AI is not a catch-all solution, it serves as a powerful tool to enhance efficiency and solid traceability through data-driven change management in medical device manufacturing and registrations. By leveraging intelligent automation, predictive impact analysis, and a unified digital thread, MedTech companies can accelerate timelines, minimize risk, and expand globally with assurance.

AI is not a silver bullet, but it is a *force multiplier* for disciplined, compliant, and fast change management in medical device manufacturing and registrations. Success relies on solid governance, clear explanations, and a human-in-the-loop operating model throughout the QARA processes. Rather than replacing human expertise, AI will augment it, enabling MedTech professionals to focus on strategic, ethical, and patient-centric decisions. When applied specifically and effectively, AI can transform change control from routine documentation into a strategic asset — benefiting teams, regulators, and most importantly, patients.

About the authors

ANUSHA GANGADHARA
Associate Director,
Product Owner,
SmartSolve Quality
and Regulatory Solution, IQVIA

DR. SANJA MATERN
Director,
Regulatory Affairs, Regulatory
Information Management,
Fresenius Medical Care

Anusha is a distinguished Product Owner specializing in Regulatory and Compliance platforms, with a proven track record of designing and delivering enterprise-scale solutions. Her expertise spans across the full scope of product management activities — defining product vision, roadmap, translating global regulatory requirements and standards into innovative, AI-enabled product capabilities, and driving cross-functional teams to ensure audit-grade compliant software applications. She is an expert in driving Agile execution and building platforms that meet rigorous global data integrity and quality expectations, positioning organizations for success in the evolving quality and regulatory landscape. Prior to IQVIA, Anusha gained extensive experience managing global submissions and market launches at Philips Healthcare and two innovative MedTech device companies incubated through Stanford University's prestigious Biodesign Program. These roles provided her with a robust foundation and comprehensive hands-on experience in compliance industry. Anusha holds a master's degree in electrical engineering from the National University of Singapore (NUS).

Sanja Matern is an experienced Regulatory Affairs leader with a PhD in Biology and RAPS RAC Device Certification, specialized in regulatory-compliant product development and global registration of innovative medical devices and in vitro diagnostics. With extensive expertise in regulatory affairs and quality management, Sanja successfully led worldwide submissions, including U.S. FDA and Notified Body approvals, and contributed to multiple Quality Award–winning projects. In her last roles she is focused on Regulatory Information Management, regulatory strategy and processes at Fresenius Medical Care, with the goal of making global submissions a continued success story.

IQVIA

TECHNOLOGIES